About Maze Therapeutics
Maze Therapeutics is a publicly listed company based in Redwood City (United States) founded in 2018. Genetic biomarkers are developed for neurological, metabolic, and renal diseases. Maze Therapeutics has raised $496 million across 5 funding rounds from investors including Janus Henderson Investors, Piper Sandler and Driehaus. The company has 125 employees. Its chief executive, as recorded, is Jason Coloma. Its focus areas include Life Sciences, Genomics, Genomics Research and Biomarker Discovery. Its competitors include Metabolon, Alector and Seer; 3 of its 3 listed competitors have raised funding.
Company details
Maze Therapeutics was founded in 2018 and is headquartered in Redwood City, United States. Genetic biomarkers and integrated technologies are developed to identify modifiers in neurological, metabolic, and renal diseases. Operations extend to oncology, with a focus on therapeutic applications in the biotechnology sector. Research efforts target disease mechanisms through genetic analysis.
- Headquarters Redwood City, United States
- Employees 125
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website mazetx.com
- Social LinkedIn X
- Legal Name Maze Therapeutics, Inc.
- Net Profit-$131.12 M (USD)-813.5as on Dec 31, 2025
- EBITDA-$140.5 M (USD)-330.76as on Dec 31, 2025
- Total Equity Funding$496M (USD)
in 5 rounds
- Latest Funding Round$150M (USD), Post-IPO
Sep 2025
- InvestorsJanus Henderson Investors
& 22 more
- Employee Count125
Funding Insights of Maze Therapeutics
Maze Therapeutics has successfully raised a total of $496M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $496M
- Total Rounds 5
- Last Round Post-IPO — $150M
- First Round $191M
(Mar 2019)
- Investors Count 23
All 5 funding rounds of Maze Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2025 | $150M | Post-IPO | – | – | |
| Dec 2024 | $115M | Series D | – | Deep Track Capital, Frazier Life Sciences | |
| Jan 2022 | $190M | Series C | – | Matrix Capital Management | |
| Oct 2019 | Series C | – | City Hill Ventures | – | |
| Mar 2019 | $191M | Series C | – | Third Rock Ventures, Arch Venture Partners |
23 investors in total: 23 institutional.
Investors in Maze Therapeutics
Maze Therapeutics has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include Janus Henderson Investors, Piper Sandler and Driehaus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Deep Track Capital is engaged in biotechnology investment activities. | deeptrackcapital.com | Greenwich, United States | ||
Healthcare investment firm focused on novel therapeutics development. | frazierls.com | Palo Alto, United States | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Investment and transformation services for entrepreneurs in technology and finance sectors. | generalcatalyst.com | |||
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com |
Investor details for Maze Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Maze Therapeutics
31 people are tracked at Maze Therapeutics (15 in leadership, 9 in board & advisors, 7 in team); the tracked headcount is 125.
| Name | Role | Group |
|---|---|---|
Jason Coloma | CEO | Leadership |
Danielle Branch | Director, Patient Advocacy And Community Engagement | Leadership |
Vicky Chang | Associate Director, Technical Accounting And Reporting | Leadership |
Kim Buck | Associate Director, Head Of Talent Acquisition | Leadership |
Marian Andrade Gamboa | Senior Director | Leadership |
Harold S. Bernstein, MD PhD | President of Research & Development | Chief Medical Officer | Leadership |
Amy Bachrodt | VP, Finance | Leadership |
Andrew Good | Vice President, Controller | Leadership |
Belinda de Leon | Director Project Management | Leadership |
Harold Bernstein | President, Research & Development & Chief Medical Officer | Leadership |
Susan Limb | Vp, Clinical Science | Leadership |
Laura Sanman | Associate Director, New Target Biology | Leadership |
Saleem Achak | Associate Director Of Procurement | Leadership |
David Palubicki, CPA | Director Of Accounting, Assistant Controller | Leadership |
Julie Ullman | Director Translational Sciences | Leadership |
Nancy Andrews | Board Member | Board & advisors |
Jeffrey Tong | Board Member | Board & advisors |
Jonathan Lim | Board Member | Board & advisors |
Richard Scheller | Board Member | Board & advisors |
Daniel K. Spiegelman | Board Member | Board & advisors |
11 more people are available in the full profile.
Complete people profiles for Maze Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Maze Therapeutics
Maze Therapeutics is a publicly listed company on the NASDAQ with ticker symbol MAZE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Jan 2025
- Listed onNASDAQ: MAZE
- Listed entityMaze Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS5787841007
- Share price$26.66 (-3.75% on the day) · 2026-10-13
- Market capitalisation$1.48B
- EPS (diluted, trailing year)$-2.53
- Volume (last session)615,147
Financials of Maze Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$131.1M | -$140.5M | |
| 2024 | $167.5M | $18.4M | $60.9M |
| 2023 | -$100.4M | -$94.5M | |
| 2022 | -$114.9M | -$107.2M |
Detailed financial statements for Maze Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Maze Therapeutics
4 dated milestones of Maze Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Maze Therapeutics is founded.
- Funding First funding round of $191.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $150.0M.
Competitors of Maze Therapeutics
Maze Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Metabolon, Alector and Seer.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| metabolon.com | 2000 | Morrisville, United States | $165.87M | 189 | Solutions for biomarker discovery and diagnostic testing are provided. | |
| alector.com | 2013 | San Francisco, United States | $214.78M | 211 | Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | |
| seer.bio | 2017 | San Francisco, United States | $127.5M | 89 | Proteomics platform developed for early cancer and neurological disease detection. |
Detailed competitors of Maze Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Maze Therapeutics
The website of Maze Therapeutics (mazetx.com) receives about 9.2K visits a month and ranks #2,405,150 among all websites worldwide, #3,293 in Biotechnology and Pharmaceuticals.
- Monthly visits9.2K
▲ 10.1% vs previous month
- Unique visitors3.6K
per month
- Global rank#2,405,150
among all websites
- Category rank#3,293
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit2.2
- Average visit1 min 04 sec
- DevicesDesktop 51% · Mobile 49%
Websites whose visitors overlap most with Maze Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| assemblybio.com | 100% | 5.8K | #3,402,677 | View details | |
| mbcbiolabs.com | 100% | #2,013,343 | View details | ||
| astellasgenetherapies.com | 100% | 1K | View details | ||
| allogene.com | 99% | 33.5K | #1,405,171 | View details | |
| sutrobio.com | 98% | 12.4K | #2,081,214 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 33 similar websites and full traffic analytics for Maze Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 33 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Maze Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Maze Therapeutics
Complete news archive for Maze Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Maze Therapeutics
Maze Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Maze Therapeutics is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Jason Coloma is the CEO of Maze Therapeutics, as recorded in our data.
Maze Therapeutics is a funded company, having raised a total of $496M across 5 funding rounds to date. The company's 1st funding round was a Series C of $191M, raised on Mar 2019.
Maze Therapeutics has 125 employees.
Maze Therapeutics was founded in 2018 and is headquartered in Redwood City, United States. Genetic biomarkers and integrated technologies are developed to identify modifiers in neurological, metabolic, and renal diseases. Operations extend to oncology, with a focus on therapeutic applications in the biotechnology sector. Research efforts target disease mechanisms through genetic analysis.
Yes, Maze Therapeutics is publicly traded on NASDAQ under the ticker symbol MAZE.
Maze Therapeutics has 23 investors. Key investors include Janus Henderson Investors, Piper Sandler, Driehaus, Arch Venture Partners, and Deep Track Capital.